Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 12:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 13,990 matching trials from the live ClinicalTrials.gov search.
Conditions
Non-hematologic Malignancy
Interventions
Sapanisertib, Paclitaxel
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Scottsdale, Arizona • Sarasota, Florida • Oklahoma City, Oklahoma + 2 more
Conditions
Solid Tumors, Glioblastoma, Recurrent Malignant Gliomas
Interventions
CTO, CTO and Temodar®, CTO, Temodar®, Radiation therapy
Drug
Lead sponsor
Tactical Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
4
States / cities
New York, New York • Portland, Oregon
Conditions
Gastro-Esophageal Junction Adenocarcinoma, Gastric Cancer
Interventions
Nab-paclitaxel 150 mg/m^2, Oxaliplatin 85 mg/m^2, 5-FU 1200 mg/m^2 x 2 D, Leucovorin 400 mg/m^2
Drug
Lead sponsor
Al B. Benson, III, MD
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
8
States / cities
Chicago, Illinois • Lake Forest, Illinois • Iowa City, Iowa + 4 more
Conditions
HIV Infections, Hemophilia A
Interventions
Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years and older · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Valsartan 160 mg + nateglinide 60 mg, Valsartan 160 mg + nateglinide placebo, Nateglinide 60 mg + valsartan placebo, Valsartan placebo + nateglinide placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 99 Years
Enrollment
9,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Multiple Locations, New Jersey
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Unresectable Breast Carcinoma
Interventions
Biopsy, Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Veliparib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2024
U.S. locations
22
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 12 more
Conditions
Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
oxaliplatin, leucovorin calcium, fluorouracil, bevacizumab, yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A, laboratory biomarker analysis, pharmacological study, irinotecan hydrochloride
Drug · Biological · Radiation + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Duarte, California
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Nevirapine, Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 17 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
58
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 39 more
Conditions
Lymphoma
Interventions
rituximab, bortezomib, Ibritumomab tiuxetan
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
Atlanta, Georgia • Chicago, Illinois
Conditions
Cancer
Interventions
GSK2118436, GSK1120212, Other approved anti-cancer agent
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
25
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Tucson, Arizona + 19 more
Conditions
Lymphoma
Interventions
Glofitamab, Tocilizumab, Doxorubicin, Vincristine, Prednisone, Rituximab, Cyclophosphamide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
10
States / cities
Duarte, California • Stanford, California • Iowa City, Iowa + 6 more
Conditions
Mycoses, Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Azithromycin, Rifabutin, Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
12
States / cities
Los Angeles, California • Orange, California • San Diego, California + 7 more
Active, not recruiting No phase listed Observational

EndeavorOTC™ Prospective Product Registry

NCT06109051
Conditions
ADHD
Interventions
EndeavorOTC
Device
Lead sponsor
Akili Interactive Labs, Inc.
Industry
Eligibility
Not listed
Enrollment
198 participants
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Liver Cancer
Interventions
bevacizumab, erlotinib hydrochloride, sorafenib tosylate
Biological · Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 116 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • New York, New York + 3 more
Conditions
Multiple Myeloma
Interventions
Pomalidomide, Bortezomib, Dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
6
States / cities
Atlanta, Georgia • Boston, Massachusetts • Hackensack, New Jersey + 1 more
Conditions
Opioid-use Disorder, Medication Adherence, Health Care Utilization
Interventions
Behavioral Activation (BA) Therapy, Substance Abuse and Health Navigation Counseling, Medications for Opioid Use Disorder
Behavioral · Other
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
filgrastim, carboplatin, paclitaxel, topotecan hydrochloride
Biological · Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Premenstrual Syndrome, PMS, Premenstrual Dysphoric Disorder, PMDD, Depression
Interventions
Ethinyl Estradiol/Drospirenone, Placebo, CDB 2914
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Biphenotypic Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
Interventions
MRI and cognitive evaluation, brain MRI study and a brief neuropsychological evaluation
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2015
U.S. locations
2
States / cities
New York, New York
Conditions
Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma
Interventions
aldesleukin, filgrastim, cyclophosphamide, etoposide, radiation therapy, peripheral blood stem cell transplantation, bone marrow ablation with stem cell support
Biological · Drug · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years to 60 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
DPX-Survivac, low dose cyclophosphamide (oral)
Biological · Drug
Lead sponsor
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Industry
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
Buffalo, New York • Mineola, New York • Durham, North Carolina + 2 more
Conditions
Hypercholesterolemia, Familial, Hyperlipidemia
Interventions
torcetrapib/atorvastatin, atorvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
14
States / cities
San Diego, California • Washington D.C., District of Columbia • Lutz, Florida + 11 more
Conditions
Advanced Ovarian Cancer
Interventions
Bevacizumab, Durvalumab, Olaparib, Placebo olaparib, Durvalumab placebo, Carboplatin+Paclitaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
1,407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
26
States / cities
Foothill Ranch, California • Los Angeles, California • Orange, California + 22 more
Conditions
Cervical Cancer, Cervical Intraepithelial Neoplasia Grade 2, Cervical Intraepithelial Neoplasia Grade 3
Interventions
motexafin lutetium, photodynamic therapy, loop electrosurgical excision procedure, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 65 Years · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania